Azacitidine

This episode is hosted by Dr. Laura Michaels.

She discusses Ziftaminib with Phenetoclax and Azacitidine Relapsed Refractory NPM1 Mutated Acute Myeloid Leukemia with Dr. Harry Erba.

She also talks with Dr. Saira Ahmed regarding her article on Durable Efficacy and Manageable Long-Term Safety of Lysocaptogene Marilucel in 3L Plus FL, 3-Year Update from TranscendFL.gov.

I'm happy to welcome Dr. Harry Erba to the Blood Podcast today.

Well, that's an excellent question there about what is the benefit of azacitidine or other hypomethylating agents.

Basically, it's been incorporated into the doublets, like with venetoclax, and now into triplets because that is where we started.

Azacitidine alone did not show a survival benefit compared to investigator choice of intervention, including best supportive care.

The independent benefit of azacitidine when you're starting to talk about targeted therapies is really unclear, especially now when we're talking about venetoclax alone, because venetoclax as a single agent does have some activity in AML, specifically in IDH mutated and NPM1-mutated patients.